Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes by Kazuhiro Kakimi, Hirokazu Matsushita, Masaaki Komatsu, Eiryo Kawakami, Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Katsuyuki Shiroguchi, Heiichiro Udono

“…Background Metformin (Met) is the first-line treatment for type 2 diabetes mellitus and plays an effective role in treating various diseases, such as cardiovascular disease, neurodegenerative disease, cancer, and aging. However, the underlying mechanism of Met-dependent antitumor immunity remains to be elucidated.Methods MitoTEMPO, a scavenger of mitochondrial superoxide, abolished the antitumor effect of Met, but not antiprogrammed cell death (PD-1) antibody (Ab) treatment. …”
Get full text

Efficacy and safety of combined low‐dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy by Ying Du, Qi Yan, Chuan Li, Wenping Zhu, Chao Zhao, Yunfeng Hao, Lin Li, Dan Yao, Xuan Zhou, Ying Li, Yuting Dang, Rong Zhang, Lin Han, Yuanyuan Wang, Tao Hou, Juan Li, Hailin Li, Panpan Jiang, Pei Wang, Fenying Chen, Tingge Zhu, Juntong Liu, Shuyu Liu, Lan Gao, Yingjun Zhao, Wei Zhang

Get full text